Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (PIQ) completes a study targeting oesophageal adenocarcinoma cancer
- Proteomics International and QIMR Berghofer are collaborating on the development of a simple blood test for oesophageal adenocarcinom
- The results showed several protein biomarkers were statistically effective in identifying oesophageal adenocarcinoma
- The teams will finalise arrangements for the future development of the biomarkers into a diagnostic test
- Proteomics International Laboratories Ltd (PIQ) last traded at $0.98 per share before market open on Febuary 4
Proteomics International Laboratories (PIQ) successfully completes its validation study targeting oesophageal adenocarcinoma cancer.
Proteomics International and QIMR Berghofer are collaborating on the development of a simple blood test for oesophageal adenocarcinoma using a panel of biomarkers, or protein ‘fingerprints’ in the blood, identified by QIMR Berghofer researchers.
The analysis tried to demonstrate the strength of the biomarkers across laboratories through a series of analytical and clinical validation experiments.
It was built on the company’s experience from developing the PromarkerD assay, the world’s first test for predicting diabetic kidney disease.
Proteomics International and QIMR Berghofer will finalise arrangements for the future development of the biomarkers into a diagnostic test for oesophageal cancer.
Proteomics International managing director, Dr Richard Lipscombe, stated the research studied multiple proteins in the blood associated with early-stage oesophageal adenocarcinoma.
“From these, we’ve been able to identify a select panel of biomarkers with the potential to be used as a diagnostic test importantly we have also completed validation of the panel using blood samples from more than 300 patients,” he said.
The results showed several protein biomarkers were statistically effective in identifying oesophageal adenocarcinoma.
The outcomes of the study will be presented today at the annual conference of the Australasian Proteomics Society in Victoria.
The study focused on Barrett’s oesophagus which is a pre-malignant condition that is a major risk factor for oesophageal adenocarcinoma.
Barrett’s oesophagus affects about two per cent of the population and occurs when the oesophagus is damaged by acid reflux.
Patients are currently screened using invasive and costly endoscopy procedures.
Proteomics International Laboratories Ltd (PIQ) last traded at $0.98 per share before market open on February 4.
